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STUDY QUESTION: Can plasma miRNAs be used for the non-invasive diagnosis of endometriosis in infertile women?
SUMMARY ANSWER: miRNA-based diagnostic models for endometriosis failed the test of independent validation.
WHAT IS KNOWN ALREADY: Circulating miRNAs have been described to be differentially expressed in patients with endometriosis
compared with women without endometriosis, suggesting that they could be used for the non-invasive diagnosis of endometriosis. However,
these studies have shown limited consistency or conflicting results, and no miRNA-based diagnostic test has been validated in an independent
patient cohort.
STUDY DESIGN, SIZE, DURATION: We performed genome-wide miRNA expression profiling by small RNA sequencing to identify a
set of plasma miRNAs with discriminative potential between patients with and without endometriosis. Expression of this set of miRNAs was
confirmed by RT-qPCR. Diagnostic models were built using multivariate logistic regression with stepwise feature selection. In a final step, the
models were tested for validation in an independent patient cohort.
PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Plasma of all patients was available in the biobank of the Leuven Endometriosis
Centre of Excellence. Biomarker discovery and model development were performed in a discovery cohort of 120 patients (controls= 38,
endometriosis= 82), and models were tested for validation in an independent cohort of 90 patients (controls= 30, endometriosis= 60).
RNA was extracted with the miRNeasy Plasma Kit. Genome-wide miRNA expression analysis was done by small RNA sequencing using the
NEBNext small RNA library prep kit and the NextSeq 500 System. cDNA synthesis and qPCR were performed using the Qiagen miScript
technology.
MAIN RESULTS AND THE ROLE OF CHANCE: We identified a set of 42 miRNAs with discriminative power between patients with
and without endometriosis based on genome-wide miRNA expression profiling. Expression of 41 miRNAs was confirmed by RT-qPCR, and 3
diagnostic models were built. Only the model for minimal–mild endometriosis (Model 2: hsa-miR-125b-5p, hsa-miR-28-5p and hsa-miR-29a-
3p) had diagnostic power above chance performance in the independent validation (AUC= 60%) with an acceptable sensitivity (78%) but poor
specificity (37%).
LIMITATIONS, REASONS FOR CAUTION: The diagnostic models were built and tested for validation in two patient cohorts from a
single tertiary endometriosis centre. Further validation tests in large cohorts with patients from multiple endometriosis centres are needed.
WIDER IMPLICATION OF THE FINDINGS: Our study supports a possible biological link between certain miRNAs and endometriosis,
but the potential of these miRNAs as clinically useful biomarkers is questionable in women with infertility. Large studies in well-described
patient cohorts, with rigorous methodology for miRNA expression analysis, sufficient statistical power and an independent validation step, are
necessary to answer the question of whether miRNAs can be used as diagnostics markers for endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): The project was funded by a grant from the Research Foundation - Flanders (FWO).
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Introduction
Endometriosis, defined as the presence of endometrial-like tissue
outside the uterus, is a chronic gynaecological disease with an overall
prevalence of 2–10% in women of reproductive age and up to 50% in
infertile women (Giudice, 2010). Patients with endometriosis can be
asymptomatic but typically present with chronic pelvic pain, infertility
or both. Due to its chronic character, lack of medical treatment and
debilitating symptoms, endometriosis results inmajor public health care
costs, comparable to that of Crohn’s disease (Simoens et al., 2012).
Endometriosis appears as superficial peritoneal lesions, adhesions,
ovarian endometriotic cysts and deeply infiltrative disease and is clas-
sified according to the staging system of the American Society for
Reproductive Investigation (ASRM) into four stages (minimal, mild,
moderate and severe disease) (1997). Ultrasound can detect ovarian
endometriotic cysts and deep endometriotic nodules but does not rule
out peritoneal endometriosis or endometriosis-associated adhesions
(Nisenblat et al., 2016). At present, there is no non-invasive test for
endometriosis. Hence, the gold standard for diagnosis is still laparo-
scopic visualization of lesions confirmed by histology (Dunselman et al.,
2014). Several studies have reported diagnostic delays in endometriosis
averaging between 4–10 years (Dunselman et al., 2014). The lack of a
non-invasive test is an important contributing factor to this diagnos-
tic delay. Non-invasive diagnosis of endometriosis would allow early
diagnosis and treatment, with the potential to improve quality of life
and reduce the costs related to endometriosis. It has therefore been
selected as a research priority by the World Endometriosis Society
and the World Endometriosis Research Foundation (Rogers et al.,
2017).
MicroRNAs (miRNAs) are a class of small non-coding regulatory
RNAs estimated to influence the translation of mRNAs in 30% of all
genes in animals (Santamaria and Taylor, 2014). At present, more than
2400 human miRNAs have been identified and registered in the miR-
Base database (Santamaria and Taylor, 2014). miRNAs control gene
expression post-transcriptionally by inhibiting translation or promoting
mRNA degradation in the cytoplasm (Moreno-Moya et al., 2014).
miRNAs are expressed in all tissues and regulate a wide spectrum of
processes, including cellular differentiation, proliferation and apoptosis
(Moreno-Moya et al., 2014). Although most miRNAs are localized
inside the cell, a significant number of miRNAs have also been detected
in extracellular body fluids such as serum, plasma, spinal fluid, follicular
fluid, saliva and urine (Traver et al., 2014).
Several studies have indicated that a large number of miRNAs are
involved in endometriosis, showing differential expression between
eutopic and ectopic endometrial tissues (Teague et al., 2010, Braza-
-Boils et al., 2014, Nothnick 2017, Haikalis et al., 2018, Panir et al.,
2018, Rekker et al., 2018, Zhao et al., 2018). Several of these dif-
ferentially expressed miRNAs are known to regulate genes involved
in processes that are crucial for the establishment and progression
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of endometriosis, such as angiogenesis, inflammation and immune
regulation (Santamaria and Taylor, 2014). Further investigation of the
expression profiles of miRNAs could lead to new insights in the
pathophysiology of endometriosis and major improvements in the
management of endometriosis (Santamaria and Taylor, 2014).
MiRNAs have also become a major focus of research aimed at
identifying new nucleic acid–based biomarkers for human disease.
MiRNAs present in serum or plasma are bound to (lipo) proteins
or localized inside exosomes, which protects them from endogenous
RNase activity (Moreno-Moya et al., 2014). Several studies have eval-
uated the potential of circulating miRNAs as diagnostic marker for
endometriosis (Jia et al., 2013; Suryawanshi et al., 2013; Wang et al.,
2013; Hsu et al., 2014; Cho et al., 2015; Rekker et al., 2015; Cosar
et al., 2016; Nothnick et al., 2016;Wang et al., 2016; Bashti et al., 2018;
Maged et al., 2018; Pateisky et al., 2018). However, these studies have
shown limited consistency and conflicting results.
The goal of this study was to discover and validate plasma miRNAs
that can be used for the non-invasive diagnosis of endometriosis.
We performed a genome-wide miRNA expression analysis in a large
discovery cohort to identify a set of plasmamiRNAswith discriminative
potential between patients with and without endometriosis. This set of
miRNAs was used to build diagnostic models for endometriosis then
tested for validation in an independent patient cohort.
Materials and Methods
The project consisted of three parts: (i) biomarker discovery based on
a genome-wide miRNA expression profiling by small RNA sequencing,
(ii) development of diagnostic models based on targeted expression
profiling using RT-qPCR for selected miRNAs and (iii) validation tests
of the diagnostic models in an independent cohort (Fig. 1). All patients
had signed a written informed consent prior to recruitment, and the
study protocol was approved by the Institutional Ethical and Review
Board of University Hospital Leuven (Belgium).
MiRNA biomarker discovery
Discovery cohort
In the first part of our study, we analysed the plasmamiRNAexpression
profile of 120 patients from the biobank of the Leuven Endometriosis
Center of Excellence. All patients had laparoscopically and histologi-
cally proven presence (n=82) or absence (n=38) of endometriosis
and had not used any hormonal medication in the 3 months prior
to laparoscopy. Patients who had a visual diagnosis of endometriosis
during laparoscopy that was not confirmed by histology were not
selected. In the control group, we only selected patients without
endometriosis lesions during laparoscopic inspection. Blood had been
collected in EDTA tubes on the day of laparoscopy before induction
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Figure 1 Overview of the project.
of anaesthesia. Within 1 h, samples were centrifuged at 1400×g for
10 min at 4◦C, then aliquoted, labelled and stored at −80◦C until
analysis. The plasma samples were obtained during the different phases
of themenstrual cycle (menstrual n=25, follicular n=43, luteal n=52).
The cycle phase identification was based on histological examination
of an endometrial biopsy taken during laparoscopy. Women with
endometriosis were classified as minimal/mild or moderate/severe
disease (ASRM endometriosis stages: I–II n=41 and III–IV n=41)
(1997). Patient characteristics are summarized in Table I.
Small RNA sequencing
RNA was extracted from 200 μl of plasma using the miRNeasy
Serum/Plasma Kit (Qiagen, Germany) according to the manufacturer’s
protocol. Libraries for small RNA sequencing were prepared using
the NEBNext Small RNA Library Prep Set for Illumina (New England
Biolabs, USA). Briefly, 6 μl of total RNA was used as the input for
RNA adapter ligation (using 3′ and 5′ RNA adapters) prior to reverse
transcription and PCR amplification with bar-coded primers. The PCR
products were pooled based on equal volumes then used for size
selection on a Pippin Prep (Sage Science, USA) to recover the fractions
containing mature miRNAs. The resulting small RNA libraries were
concentrated by ethanol precipitation and quantified using a Qubit 2.0
Fluorometer (Thermo Fisher Scientific, USA) prior to sequencing on a
NextSeq 500 sequencer (Illumina, USA) with read lengths of 75 base
pairs and 15 million single-end reads per sample, on average.
Sequencing reads were processed using the data processing pipeline
Cobra (Biogazelle, Belgium). First, reads were filtered based on
stringent read quality control. After adapter trimming, reads were
collapsed and mapped to the reference genome (Homo sapiens,
GRC38) using Bowtie (Langmead et al., 2009). Mapped reads were
subsequently annotated to different contaminants (tRNA fragments,
rRNA, sn(o) RNA, piRNA, etc.) and mature miRNAs using genome
annotation data from Ensembl 76, UCSC and miRBase v21. We used
the sum of all isomiR reads from the canonical mature miRNA locus
for miRNA expression analysis. Prior to normalization, data were
filtered using a cut-off of 4fourreads (i.e. only those miRNAs with four
or more reads were considered expressed). miRNA expression data
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were normalized based on the total read count per sample, i.e. the
read count for each miRNA was divided by the total read count in
that sample and multiplied by the median total read count across all
samples. After this normalization step, the data were log2 transformed.
To assess possible hemolysis, we calculated the miR-Ratio, i.e. the fold
change between hsa-miR-451a and hsa-miR-23a-3p (Blondal et al.,
2013, Shah et al., 2016).
Signature selection
Differentially expressed miRNAs were identified using a Mann–
Whitney U test on the normalized miRNA expression data, followed
by multiple testing correction according to the Benjamini–Hochberg
method. Only miRNAs that were expressed in 80% of samples of
either one of both analysed patient subgroups were included.
Multivariate logistic regression with stepwise feature selection was
used to select miRNAs with discriminative potential between disease
and controls. We performed three comparisons (all disease versus
all controls, all stage I–II versus all controls and all stage III–IV versus
all controls) in all cycle phases combined and in the separate cycle
phases (menstrual, follicular and luteal), resulting in a total of 12
analyses. Only miRNAs that were expressed in 80% of samples of
either one of both analysed patient subgroups were included. We
selected the top 10 discriminative miRNAs from the 12 analyses for
targeted miRNA profiling with RT-qPCR. Due to significant overlap
between the different analyses, this resulted in a panel of 42 miRNAs.
Development of the diagnostic model
In the second part of our study, we performed a targeted plasma
miRNA expression profiling with RT-qPCR for the set of 42 miRNAs
selected in the first part of the project. We used the same discov-
ery cohort (n=120) from the biobank of the Leuven Endometriosis
Center of Excellence. RNA had already been extracted prior to small
RNA sequencing profiling.
To identify candidate reference miRNAs, stably expressed in the
sample cohort, we selected miRNAs expressed in all samples based on
the available small RNA sequencing data. Subsequently, we calculated
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/9/1650/5549383 by G
hent U
niversity user on 16 June 2020
Plasma miRNAs as biomarkers for endometriosis 1653
Table I Patient characteristics of the discovery and validation cohort.
Discovery cohort (n =120) Validation cohort (n =90)
................................................................ ..............................................................
Controls
(n =38)
Endometriosis
(n =82)
All
(n =120) 1P-value
Controls
(n =30)
Endometriosis
(n =60)
All
(n =90) 1P-value 2P-value
........................................................................................................................................................................................
Age (years,mean±SD) 30± 4 32± 4 31± 4 0.007 31± 5 31± 4 31± 4 0.855 0.324
BMI (kg/m2,mean±SD) 23.6± 3.6 22.5± 5.1 22.8± 4.7 0.224 24.0± 3.5 21.6± 2.7 22.4± 3.2 0.001 0.495
Smoking, n (%) 11 (29%) 11 (13%) 22 (18%) 0.097 11 (37%) 13 (22%) 24 (27%) 0.193 0.124
Cycle phase, n (%)
Menstrual 8 (21%) 17 (21%) 25 (21%) 0.597 4 (13%) 7 (12%) 11 (12%) 0.820 0.459
Follicular 13 (34%) 30 (37%) 43 (36%) 0.978 13 (43%) 26 (43%) 39 (43%) 1.000 0.297
Luteal 17 (45%) 35 (43%) 52 (43%) 0.586 13 (43%) 27 (45%) 40 (44%) 0.881 0.660
Infertility, n (%)
All infertility 35 (92%) 78 (95%) 113 (94%) 0.928 30 (100%) 59 (98%) 89 (99%) 0.477 0.120
Primary 21 (55%) 61 (74%) 82 (68%) 0.036 17 (57%) 45 (75%) 62 (69%) 0.126 0.932
Secondary 14 (37%) 17 (21%) 31 (26%) 0.061 13 (43%) 14 (23%) 27 (30%) 0.051 0.504
Pain symptoms, n (%)
Any pain symptoms 30 (79%) 73 (89%) 103 (86%) 0.161 21 (70%) 47 (78%) 68 (76%) 0.386 0.062
Dyspareunia 17 (45%) 16 (20%) 33 (28%) 0.011 4 (13%) 14 (23%) 18 (20%) 0.264 0.130
Dysmenorrhea 25 (66%) 68 (83%) 93 (78%) 0.037 19 (63%) 45 (75%) 64 (71%) 0.129 0.486
Dyschezia 2 (5%) 5 (6%) 7 (6%) 0.407 4 (13%) 1 (2%) 5 (6%) 0.015 0.652
Chronic pelvic pain 5 (13%) 12 (15%) 17 (14%) 0.829 2 (7%) 10 (17%) 12 (13%) 0.681 0.779
ASRM stage, n (%)
Stage I-II NA 41 (50%) NA NA NA 41 (68%) NA NA 0.029
Stage III-IV NA 41 (50%) NA NA NA 19 (32%) NA NA 0.029
Ultrasound-negative
endometriosis n (%)
NA 61 (74%) NA NA NA 50 (83%) NA NA 0.203
NA=not applicable. A t-test was used for comparison of continuous variables (age & BMI) and chi-square test for categorical variables
1Controls versus endometriosis.
2Discovery cohort versus validation cohort.
the coefficient of variation (CV) for each miRNA using the normalized
miRNA expression data. The top 10 miRNAs with lowest CV, not
belonging to the same miRNA cluster or located at the same genomic
locus, were selected for geNorm analysis (Hellemans et al., 2007). The
geNorm analysis was performed using Biogazelle’s qbase+ software
(www.qbaseplus.com) using log2-transformedmiRNA count data. This
geNorm study was characterized by medium reference target stability
(average geNorm M≤ 1.0). The optimal number of reference targets
in this experimental situation is five (geNormV< 0.15when comparing
a normalization factor based on the four or five most stable targets).
As such, the optimal normalization factor can be calculated as the
geometric mean of reference targets hsa-miR-361-3p, hsa-miR-423-
3p, hsa-miR-28-3p, hsa-miR-191-5p, hsa-miR-425-5p. These miRNAs
were considered as candidate reference miRNAs.
For cDNA preparation, 1.5 μl of total RNA was reverse transcribed
using the miScript II RT Kit (Qiagen, Germany). cDNA was pre-
amplified in a 12-cycle PCR reaction using the miScript PreAMP PCR
Kit (Qiagen, Germany). Pre-amplified cDNA was diluted and used as
input for a 40-cycle qPCR reaction, quantifying 42 candidate miRNAs
of interest, the five candidate reference miRNAs (hsa-miR-361-3p,
hsa-miR-423-3p, hsa-miR-28-3p, hsa-miR-191-5p and hsa-miR-425-5p)
and two controls (positive PCR control and miRNA reverse transcrip-
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tion control) using miScript Primer Assays (Qiagen, Germany) with the
miScript SYBR Green PCR Kit (Qiagen, Germany). All reactions were
performed in 384-well plates on the CFX instrument (Bio-Rad, USA)
using the gene maximization strategy. Cq-values were determined
based on the single threshold algorithm and filtered using a detection
cut-off of 29 cycles.
To confirm candidate reference miRNAs, a geNorm pilot exper-
iment was performed using the RT-qPCR data of five candidate
reference miRNAs on all samples. Data analysis was performed
using qbase+ software (www.qbaseplus.com) (Biogazelle, Belgium).
This geNorm study was characterized by high reference target
stability (average geNorm M≤ 0.5). The optimal number of reference
targets in this experimental situation is two (geNorm V< 0.15 when
comparing a normalization factor based on the two or three most
stable targets). As such, the optimal normalization factor can be
calculated as the geometric mean of reference targets hsa-miR-28-
3p and hsa-miR-423-3p.
Model building
Diagnostic models were built using multivariate logistic regression with
stepwise feature selection and a 5% significance level for variables to
enter or stay in the model. We built three diagnostic models: the first
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model to discriminate between controls and all patients with endome-
triosis and the second and third models to discriminate between
controls and patients with minimal–mild (stage I–II) or moderate–
severe (stage III–IV) endometriosis, respectively. To determine the
optimal cut-off for the diagnostic models, the Youden index was used.
Validation in independent cohort
In the final part of our study, we validated the diagnostic models in
an independent validation cohort of 90 patients from the biobank
of the Leuven Endometriosis Center of Excellence. All patients had
laparoscopically and histologically proven presence (n=60) or absence
(n=30) of endometriosis and had not used any hormonal medication
in the 3 months before laparoscopy. Plasma was collected on the day
of laparoscopy before induction of anaesthesia. The plasma samples
were obtained during the different phases of the menstrual cycle
(menstrual n=11, follicular n=39, luteal n=40). The cycle phase
was based on histological examination of an endometrial biopsy taken
during laparoscopy.Women with endometriosis were classified as min-
imal/mild or moderate/severe disease (ASRM endometriosis stages:
I–II n=41, III–IV n=19) (1997). Patient demographics are summarized
in Table I. RNA extraction, cDNA synthesis and qPCRwere performed
with the same technology and protocols as described for the discovery
cohort. Themodel algorithm trained in the discovery cohort was tested
in this independent test set.
Results
Description of the discovery and validation
cohort
The clinical characteristics of the patients from the discovery and
validation cohort are presented in Table I. There were no significant
differences between the discovery and validation cohort, except for
the significantly larger proportion of moderate/severe endometriosis
in the discovery cohort (P=0.029).
In the discovery cohort, the endometriosis group was older (32± 4)
than the control group (30± 4). Although statistically significant
(P=0.007), it is unlikely that this small age difference is clinically
relevant. In the validation cohort, the endometriosis group had a
significantly lower BMI (21.6± 2.7) than the control group (24.0± 3.5)
(P=0.001). In both patient cohorts, there were more patients with
primary infertility in the endometriosis group than in the control
group and thus an opposite distribution in secondary infertility.
Only in the discovery cohort this reached significance (P=0.036).
In both patient cohorts, the vast majority of patients had some pain
symptoms suggestive of endometriosis. In the discovery cohort, the
endometriosis group had significantly less dyspareunia (P=0.011) and
more dysmenorrhea (P=0.037). In the validation cohort, the control
group had significantly more dyschezia (P=0.015).
Quality control of plasma samples
Visual inspection of the plasma samples to assess possible hemolysis
identified 16 out of 120 samples (13%) in the discovery cohort that
showed a discolouration: 10 samples (8%) were light orange and 6 sam-
ples (5%) were dark orange or red. In the validation cohort, 20 out of
90 samples (22%) were discoloured: 16 samples light orange (18%) and
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4 samples (4%) dark orange or red (4%). Using the miR-Ratio thresh-
olds of 5 and 7 for assessment of hemolysis in our discovery cohort,
we found 39 samples had a low risk of hemolysis (miR-Ratio <5), 31
samples had an intermediate risk (5<miR-Ratio<7) and 50 samples
had a high risk of hemolysis (miR-ratio >7) (Shah et al., 2016). There
was no significant difference in the fraction of samples at intermediate
and/or high risk of hemolysis in controls versus endometriosis patients
(P=0.44, Chi square test) (Supplementary Fig. S1). Since these
thresholds set for the detection of sample hemolysis are based on RT-
qPCR data, it is unclear if extrapolation to next generation sequencing
(NGS) data is possible. Therefore, we analysed expression of two
hemolysis sensitive miRNAs: miR-16-5p and miR-15b-5p. We did not
see an increased expression of hsa-miR-16-5p and hsa-miR-15b-3p
in the samples with a high risk for hemolysis based on the miR-Ratio
(P=0.56 and P=0.49, Kruskal–Wallis test; see Supplementary Fig. S1).
We did not see any effect of biobanking time on RNA concentration
(Supplementary Fig. S2), and there were no significant differences in
RNA concentrations between cases and controls in either the discov-
ery or validation cohorts (P=0.72 and P=0.26, Mann–Whitney U test;
Supplementary Fig. S3).
MicroRNA biomarker discovery
Two samples of control patients from the discovery cohort were
excluded from the analysis because of poor small RNA library quality.
Univariate analysis was performed for six comparisons using a Mann–
Whitney U test: all stages versus all controls, all stage I–II versus
all controls, all stage III–IV versus all controls, all disease versus all
controls in the luteal phase, all disease versus all controls in the
follicular phase and all disease versus all controls in the menstrual
phase. This resulted in 39 (28 up, 11 down), 21 (15 up, 6 down),
49 (34 up, 15 down), 24 (19 up, 5 down), 2 (2 up) and 31 (18 up,
13 down) differentially expressed (P< 0.05) miRNAs, respectively
(Supplementary Table SI). However, after correction for multiple
testing according to the Benjamini–Hochberg method, no miRNAs
remained differentially expressed (adjusted P< 0.05).
To identify miRNAs with discriminative potential between patients
with and without endometriosis, irrespective of their differential
expression in the univariate analysis, we performedmultivariate logistic
regression. Firstly, we compared cases and controls in all cycle phases
combined and in the separate cycle phases (menstrual, follicular and
luteal). Secondly, we performed a sub-analysis for minimal–mild and
moderate–severe endometriosis, resulting in a total of 12 analyses.
miRNAs were ranked according to their discriminative power, and we
selected the top 10 miRNAs from the 12 analyses for confirmation
of miRNA expression with RT-qPCR. Because of important overlap
between the top-ranked miRNAs in the different analyses, this resulted
in a panel of 42 miRNAs, as listed in Table II. Of the 42 miRNAs, 5
were differentially expressed in the univariate analysis (i.e. P< 0.05 in
minimally 1 of the 6 comparisons using Mann–Whitney U test, before
multiple testing correction) (Table II).
Development of diagnostic models
In the second part of the project, we performed a targeted miRNA
profiling for the panel of 42 miRNAs using RT-qPCR in the same
discovery cohort. However, for hsa-miR-17-5p and hsa-miR-106a-5p,
no separate qPCR primer is available in the miScript assays of Qiagen
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Table II The 42 miRNAs selected by multivariate logistic regression on the RNA-seq data.
The panel of 42 miRNAs selected for validation
........................................................................................................................................................................................
hsa-let-7a-5p hsa-miR-103a-3p hsa-miR-15b-5p hsa-miR-199b-5p hsa-miR-23a-3p hsa-miR-29b-3p
hsa-let-7b-5p hsa-miR-106a-5p hsa-miR-16-5p hsa-miR-19a-3p hsa-miR-24-3p hsa-miR-30a-3p
hsa-let-7c-5p hsa-miR-107 hsa-miR-17-3p∗ hsa-miR-19b-3p hsa-miR-25-3p hsa-miR-30a-5p
hsa-let-7d-5p hsa-miR-10a-5p hsa-miR-17-5p hsa-miR-20a-5p hsa-miR-26a-5p hsa-miR-33a-5p
hsa-let-7e-5p hsa-miR-125b-5p hsa-miR-182-5p∗ hsa-miR-21-5p∗ hsa-miR-26b-5p hsa-miR-92a-3p
hsa-let-7f-5p hsa-miR-148a-3p hsa-miR-18a-5p hsa-miR-210-3p∗ hsa-miR-28-5p hsa-miR-95-3p
hsa-miR-101-3p hsa-miR-15a-5p hsa-miR-199a-5p hsa-miR-22-3p hsa-miR-29a-3p hsa-miR-98-5p
∗Significant in the univariate analysis (before adjustment for multiple testing).
Table III Overview of the logistic regression models.
Model 1: All
endometriosis stages
Coefficient SE P-Value Optimal cut-off Diagnostic performance
........................................................................................................................................................................................
Intercept 1.000 0.236 <0.0001
0.5556
• AUC: 73% (64–83%)
• Sensitivity: 85%
• Specificity: 49%
hsa-let-7d-5p 3.219 1.363 0.0182
hsa-miR-21-5p −3.758 1.093 0.0006
hsa-miR-28-5p 5.967 2.473 0.0158
Model 2: Stage I-II
endometriosis
Coefficient SE P-Value Optimal cut-off Diagnostic performance
.......................................................................................................................................................................................
Intercept 0.321 0.271 0.2370
0.4759
• AUC: 77% (66–87%)
• Sensitivity: 80%
• Specificity: 62%
hsa-miR-125b-5p 3.551 1.221 0.0036
hsa-miR-28-5p 11.356 3.431 0.0009
hsa-miR-29a-3p −6.906 2.030 0.0007
Model 3: Stage III-IV
endometriosis
Coefficient SE P-Value Optimal cut-off Diagnostic performance
.......................................................................................................................................................................................
Intercept 0.198 0.271 0.4664
0.6247
• AUC: 81% (71–90%)
• Sensitivity: 63%
• Specificity: 89%
hsa-miR-21-5p −4.794 1.357 0.0004
hsa-miR-28-5p 11.343 3.270 0.0005
hsa-miR-30a-5p 6.874 2.610 0.0084
because only one base is different between the twomiRNA sequences.
Therefore, miRNA expression was confirmed for only 41 miRNAs.
The miScript Assay for hsa-miR-17-5p was used and quantified both
hsa-miR-17-5p and hsa-miR-106a-5p as a single miRNA. As a result,
we had 41 features (miRNAs) in the downstream data analysis.
We used multivariate logistic regression with stepwise feature
selection to build three diagnostic models for endometriosis: model
1 to discriminate between controls and patients with all stages of
endometriosis and models 2 and 3 to discriminate between controls
and patients with minimal–mild (stage I–II) or moderate–severe (stage
III–IV) endometriosis, respectively (Table III). All models consisted
of three miRNAs with hsa-miR-28-5p present in all models and hsa-
miR-21-5p present in model 1 and model 3. Model 1 (hsa-let-7d-
5p, hsa-miR-21-5p and hsa-miR-28-5p) had an AUC of 73% with a
high sensitivity (85%) but a low specificity (49%) at optimal cut-off
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(Table III). Model 2 (hsa-miR-125b-5p, hsa-miR-28-5p and hsa-miR-
29a-3p) performed slightly better with an AUC of 77% and could
detect minimal–mild endometriosis with a sensitivity of 80% and
specificity of 62% at optimal cut-off (Table III). Model 3 (hsa-miR-21-
5p, hsa-miR-28-5p and hsa-miR-30a-5p) had the best AUC (81%) with
a high specificity (89%) for stage III–IV endometriosis and a sensitivity
of 63% at optimal cut-off (Table III).
Validation of diagnostic models
In the final step of our project, we validated the diagnostic models in an
independent validation cohort (Fig. 2). Models 1 and 3 experienced a
drop in diagnostic accuracy to levels of chance performancewith AUCs
of 50% (Fig. 2). Model 2 had an AUC of 60% in the validation cohort
and could, at optimal cut-off, detect minimal–mild endometriosis with
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/9/1650/5549383 by G
hent U
niversity user on 16 June 2020
1656 Vanhie et al.
Figure 2 Validation of the diagnostic models in an independent patient cohort. Black curve = Discovery cohort; Red curve = validation
cohort. Data in the contingency tables are from the validation cohort.
an acceptable sensitivity of 78% but with a very low specificity of 37%
(Fig. 2).
Effect of menstrual cycle phase on miRNA
levels
To assess a potential effect of the phase of the menstrual cycle on
circulating miRNA levels, we compared the levels of the 41 miRNAs in
the luteal, follicular and menstrual phase (Supplementary Tables SII and
SIII). In the discovery cohort, we found 16 miRNAs with a significant
difference between the levels in either the luteal, menstrual or follicular
phase: hsa-let-7c-5p (P=0.027), hsa-miR-101-3p (P=0.004), hsa-miR-
103a-3p (P=0.009), hsa-miR-10a-5p (P=0.020), hsa-miR-125b-5p
(P=0.008), hsa-miR-17-3p (P=0.006), hsa-miR-182-5p (P=0.011),
hsa-miR-18a-5p (P=0.016), hsa-miR-199b-5p (P=0.009), hsa-miR-
210-3p (P =0.008), hsa-miR-24-3p (P=0.013), hsa-miR-25-3p
(P=0.042), hsa-miR-26a-5p (P=0.024), hsa-miR-26b-5p (P=0.030),
hsa-92a-3p (P=0.002) and hsa-miR-95-3p (P=0.008). In the validation
cohort only four miRNAs had a possible cycle effect: hsa-miR-let-7d-
5p (P=0.009), miR-15b-5p (P=0.05), hsa-miR-199a-5p (P=0.031),
hsa-miR-30a-5p (P=0.022). No miRNA had significant cycle changes
in both the discovery and validation cohort. Therefore, it is more likely
that the observed changes are due to biological variability rather than
a true menstrual cycle effect.
Discussion
In this study, we investigated whether plasma miRNAs can be used for
the non-invasive diagnosis of endometriosis. First, we identified a set
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of 42 plasma miRNAs with discriminative potential between patients
with and without endometriosis based on a genome-wide miRNA
expression profiling. Secondly, we validated miRNA expression with
RT-qPCR and developed three diagnostic models in the discovery
cohort of 120 patients. Finally, the models were validated in an inde-
pendent cohort of 90 patients. Two out of three models did not
have a diagnostic potential above chance performance in the validation
cohort. The diagnostic model for minimal–mild endometriosis had an
acceptable sensitivity of 78% but with a very low specificity of 37% and
an AUC of only 60%.
The strength of our study lies in its rigorous methodological design.
To minimize potential inaccuracies due to sample processing, our
biobank has adopted strict standard operating procedures (Fassbender
et al., 2013). All patients were operated in the Leuven Endometriosis
Center of Excellence, a tertiary care unit for endometriosis patients in
Belgium, receiving pre- and post-operative care according to a strict
clinical protocol (Meuleman et al., 2014). Staging of endometriosis was
done by two experienced endometriosis surgeons, again minimizing
potential variability. The use of standard protocols for both clinical
management and sample collection allowed us to minimize the clinical
and technical variability in the two patient cohorts.
Secondly, we used a workflow with highly validated standard oper-
ating procedures for miRNA expression analysis and data processing
to maximize the accuracy of our results. In the discovery phase,
we used next generation sequencing for miRNA expression analysis.
This state-of-the art technology is ideal for unbiased genome-wide
miRNA expression profiling. For the development and validation of
the diagnostic models, we used RT-qPCR that has high specificity and
linear dynamic range of quantification, making it the gold standard for
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expression profiling of even low abundant miRNAs. Normalization
of miRNA expression data is challenging since no standard reference
or housekeeping miRNAs have been identified. Therefore, we used
qbase+ software for data processing and normalization. This software
is built upon an established quantification model including PCR effi-
ciency correction, multiple reference gene normalization and inter-run
calibration (Hellemans et al., 2007).
Finally, we used an approach based onmultivariate logistic regression
with stepwise feature selection for development of the diagnostic
models. The multivariate statistical approach allowed us to model the
relationship between the diagnostic categories and all of the miRNAs
simultaneously, while taking into account the correlation that may exist
between the miRNAs.We specifically chose to build diagnostic models
without taking the required number of miRNAs into account since the
combination of multiple biomarkers might be necessary to capture the
complex dynamics of the endometriosis disease process. We did so
because in practice, a substantial part of the workload for miRNA
expression analysis relates to RNA extraction, which is independent
of the number of miRNAs to be analysed. The RT-qPCR can be fully
automated, and the number of analysed miRNAs has relatively little
impact on cost and time.
While our study focused on minimizing potential variability and bias,
several limitations must be addressed. Firstly, this is not a prospective
study but a retrospective, biobank-based cohort study. All patients
were selected from the biobank of the Leuven University Fertility Cen-
ter, and, as stated in the methods’ section, we excluded samples from
patients receiving hormonal suppression therapy at the time of surgery.
We included samples from patients with laparoscopically proven
presence or absence of endometriosis, with three possible indications
for surgery: surgical treatment of endometriosis diagnosed on imaging
or diagnostic laparoscopy, investigation of pain symptoms suggestive
of endometriosis or a diagnostic laparoscopy as part of the diagnostic
work-up for infertility. In routine practice in our centre, laparoscopies
in women with (unexplained) infertility are predominantly performed
when they also have pain symptoms. This explains the high pain
prevalence in both cases and controls (Table I). Furthermore, the
proportion of patients with only pain symptoms and no infertility
was rather low (Table I), because patients with pain suggestive of
endometriosis and without intention to conceive in the near future,
typically receive hormonal therapy as first line treatment. Since we
excluded samples from patients using hormonal medication at the
time of surgery, we predominantly selected samples from infertile
patients with pain symptoms suggestive of endometriosis. Finally,
excluding patients under hormonal therapy resulted in selection of
a high number of patients with ultrasound negative endometriosis
because, in our hospital, it is common practice that patients with
evidence of endometriosis on imaging (ultrasound or MRI) are given
hormonal suppression (oral contraceptives or GnRH analogues) in the
pre-operative period. Overall, our study was done in a highly selected
population of predominantly infertile women with pain symptoms
suggestive of endometriosis and a normal pelvic ultrasound. More
research is needed to confirm our data in patient populations with pain
and without infertility, but this research effort will be confounded by
the fact that many patients with endometriosis-associated pain receive
hormonal suppression therapy.
In order to address the challenge in the selection of a control
group in endometriosis biomarker studies, both our study and control
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samples were obtained from a similar and well-characterized patient
population (Table I), i.e. women with subfertility and pain symptoms
suggestive of endometriosis. Since a diagnostic laparoscopy is often
considered in these patients, they represent a relevant patient group
for which a non-invasive diagnostic test for endometriosis would be
useful (Vodolazkaia et al., 2012, Fassbender et al., 2015). To show true
promise as an aid to diagnosis, a biomarker for endometriosis needs to
distinguish women with endometriosis from unaffected women with
a similar presentation (May et al., 2010), In our study, both cases and
controls indeed had a similar clinical presentation and indication for
surgery (nearly all had infertility and a majority had pain symptoms
suggestive of endometriosis) and only differed with respect to the
presence or absence of macroscopic endometriosis confirmed by
histology.
Another important limitation of our study is the relatively small
number of patients in the two study cohorts. Although 210 patients
represent the largest cohort in which the potential of circulating
miRNAs as biomarkers for endometriosis has been studied so far, this
number still represents a relatively small population for model building.
However, the large variability and conflicting results in the existing
literature on differential expression of circulating miRNAs between
patients with and without endometriosis did not allow us to make a
reliable estimation of an expected effect size, and therefore, a formal
power calculation was not possible at the start of our study. We
attempted to address the issue of statistical power in the methodologi-
cal design of the project. We anticipated a certain degree of overfitting
in the multivariate analysis in the discovery phase. However, multiple
comparison or overfitting of a multivariate analysis does not result in
loss of significance; it results in more type 1 error. We accepted this
possibility of false positive selection of features, since we considered
the discovery phase as exploratory.
In the model building phase, we used multivariate logistic regression
with stepwise feature selection and a 5% significance level for variables
to enter or stay in the model. This technique selects the largest effects
first (i.e. the miRNAs with the best discriminative potential) and then
adds smaller effects. We recognize that the relatively small sample size
in the model building phase might have failed to detect small effects.
However, since a model combining the three largest effects did not
withstand independent validation, it seems unlikely that addition of
smaller effects (i.e. miRNAs with very limited additional discriminative
power) would have changed this observation. Ideally, the validation
cohort would have been larger. However, a small validation set does
not result in an underestimation of the AUC; it merely results in a wider
confidence interval. In our data set, a narrower confidence would not
have changed the overall conclusion for any of the three diagnostic
models.
Several studies investigating the potential of circulating miRNAs as
biomarkers for endometriosis have been published (Jia et al., 2013,
Suryawanshi et al., 2013,Wang et al., 2013, Hsu et al., 2014, Cho et al.,
2015, Rekker et al., 2015, Cosar et al., 2016, Nothnick et al., 2016,
Wang et al., 2016, Bashti et al., 2018, Maged et al., 2018, Pateisky et al.,
2018). These studies have shown differential expression of circulating
miRNAs between patients with and without endometriosis. However,
these studies have shown limited consistency or conflicting results, and
no miRNA-based diagnostic test has been validated in an independent
patient cohort so far. The disparities between the different studies
and the inability to validate initial findings can be explained by multiple
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sources of variability in miRNA research related to endometriosis.
There are pre-analytical factors such as the source of the miRNAs
(serum or plasma), type of blood collection tubes (EDTA versus
heparin), hemolysis, sample processing protocol, etc. Secondly, there
are technical factors related to the method used for RNA extraction,
miRNAs expression analysis (micro-array, RT-qPCR and NGS) and
the strategy for normalization of miRNA expression data. Finally,
there are biological factors: genetic background of the study cohort,
the control population (self-reported healthy versus laparoscopically
proven absence of endometriosis), extent of endometriosis (stage I
versus stage IV), etc.
In the discovery phase of the project, we applied a genome-wide
approach, and when we selected the panel of 42 candidate miRNAs
we noted some interesting overlap with previously published studies: 8
out 42 miRNAs in our panel had been reported as potential circulating
biomarkers for endometriosis in other studies (Jia et al., 2013, Wang
et al., 2013, Cho et al., 2015, Cosar et al., 2016). From the miRNAs
included in the three diagnostic models (hsa-let-7d-5p, hsa-miR-125b-
5p, hsa-miR-21-5p, hsa-miR-28-5p, hsa-miR-29a-3p and hsa-miR-30a-
5p), two miRNAs have been suggested as circulating biomarkers for
endometriosis (hsa-let-7d-5p and hsa-miR-125b-5p) (Cho et al., 2015,
Cosar et al., 2016), and three miRNAs have been implied to play a role
in the pathophysiology of endometriosis (hsa-miR-30a-5p, hsa-miR-
125b-5p and hsa-miR-21-5p) (Chang et al., 2013, Aoyagi et al., 2017,
Haikalis et al., 2018, Liu , 2018, Park et al., 2018). Our study supports a
possible link between these miRNAs and endometriosis. However, as
shown in our study, the potential of these miRNAs as clinically useful
biomarkers is questionable.
In our project, we tried to minimize potential biological and
technical variability by selecting the samples from the same biobank
and using identical methodology for miRNA expression analysis.
Nevertheless, we failed to validate our diagnostic models. Our
data suggest an important natural variation in circulating miRNA
levels between individuals, with only very modest or minimal
changes related to endometriosis. Interestingly, we found that, in the
independent validation cohort, the diagnostic miRNA model for stage
I–II endometriosis performed slightly better than the model for stage
III–IV endometriosis. Intuitively, one would expect a higher difference
between stage III–IV endometriosis and controls. The better diagnostic
performance from themodels for stage I–II endometriosis might reflect
an influence of endometriosis phenotype on miRNA expression. The
stage III–IV group is more heterogenous since it consists of patients
with extensive adhesions, endometriomas, deep endometriotic
nodules, etc., whereas patients in the stage I–II group almost
exclusively have peritoneal endometriosis and sometimes limited
adhesions.
Conclusion
In this study, we investigated the potential of plasma miRNAs as
biomarkers for endometriosis in women with infertility and pain. Our
study supports a possible biological link between certain miRNAs
and endometriosis. The potential of these miRNAs as clinically useful
biomarkers is questionable given the important individual natural vari-
ation in miRNA levels. Large studies in well-described patient cohorts,
with rigorous methodology for miRNA expression analysis, sufficient
statistical power and an independent validation step, are necessary
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to answer the question of whether miRNAs can be used for the
non-invasive diagnosis of endometriosis.
Supplementary data
Supplementary data are available at Human Reproduction online.
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